
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes PLC is expected to experience revenue growth through 2030, bolstered by decreasing Invega royalties and the impending patent expiry of Vivitrol, despite some offsetting factors related to the acquisition of Lumryz. The acquisition of Lumryz is projected to enhance Alkermes's financial performance with annualized sales anticipated to reach approximately $265-$275 million by 2025, with further growth expected in subsequent years, positioning the company favorably within the narcolepsy and insomnia markets. Additionally, the encouraging data from alixorexton and ongoing development programs contribute to a robust growth outlook, supported by a strong commercial base that enhances both near- and mid-term financial prospects.
Bears say
Alkermes PLC faces a negative outlook primarily due to anticipated challenges in its key product, Lumryz, including projected sales stagnation and significant patent expirations that threaten future revenue stability. The company also encounters risks from its royalty business erosion and the early-stage nature of its orexin program, which necessitates further validation in larger studies. Additionally, the competitive landscape for orexin receptor agonists is expected to intensify, potentially leading to further market share erosion and impacting long-term growth prospects.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares